Summary & Overview

Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

DRG 822 applies to hospital stays for lymphoma and leukemia cases with major operating room procedures when no Major Complication or Comorbidity or Complication or Comorbidity is present. It captures a high-resource surgical cohort and therefore has important implications for inpatient prospective payment under Medicare.

Lymphoma and Leukemia with Major O.R. Procedures without CC/MCCDRG Lymphoma and Leukemia with Major O.R. Procedures without CC/MCCDRG 822Diagnosis-Related GroupInpatient ReimbursementMedicareHematologyOncology SurgeryHospital CodingProspective Payment System

DRG 822 Overview

DRG 822 covers inpatient admissions for patients with lymphoma and leukemia who undergo major operating room procedures without Major Complication or Comorbidity or Complication or Comorbidity. It groups high-resource surgical cases involving hematologic malignancies where no additional coded complications elevate payment. This Diagnosis-Related Group matters for Medicare payment because it defines the bundled prospective payment for the hospital stay based on clinical complexity and resource use. Accurate coding of procedures and comorbidities is essential to assign the correct Diagnosis-Related Group and corresponding reimbursement level.

National Payment Rates

Payer rates for DRG 822 range from a low of $11K (Cigna minimum) up to $44K (Anthem maximum), with mean benchmarks clustering around $12K–$20K depending on payer. The widest spread observed across payers is $33K (Anthem max $44K vs Cigna min $11K). Refer to the payer benchmark table and accompanying chart below for payer-specific percentiles and distributions for Anthem, Cigna, Aetna, and BCBS.

Mean Rates by Payer — National — DRG 822

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($12.9k), average submitted covered charges ($68.8k), average Medicare payment ($9.7k), and total discharges (679) for DRG 822.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

In Alaska, DRG 822 reimburses between $19K and $29K across payers, reflecting a relatively tight state range. Cigna stands out at a mean of $29K, materially above Anthem and Blue Cross Blue Shield at $19K each and modestly higher than national Cigna benchmarks. See the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna (mean $29K); Lowest payers: Anthem and Blue Cross Blue Shield (mean $19K).
Alaska’s rates range from $19K to $29K across payers, with Cigna noticeably above both Anthem and Blue Cross Blue Shield and modestly above national means for Cigna.

Clinical Trials

Perioperative and intraoperative management trials investigating optimized surgical approaches and supportive care for patients with lymphoma or leukemia undergoing major operating room procedures; these studies enroll inpatient adults or children with active hematologic malignancies who require major resections, biopsies, or device implantations and test protocols for transfusion thresholds, perioperative antimicrobial prophylaxis, and strategies to minimize bleeding and infection risk. Research in this area addresses immediate procedural complications and resource utilization, directly informing hospital protocols, length-of-stay, and reimbursement drivers for this DRG.
Comparative effectiveness studies evaluating different systemic therapy sequencing or timing in relation to major O.R. procedures, such as trials comparing neoadjuvant versus adjuvant systemic regimens or timing of chemotherapy relative to surgery; these typically include patients with lymphoma or leukemia where surgical intervention is part of diagnostic management or symptom control, and measure outcomes like complication rates, readmissions, and short-term disease control. Findings are relevant to clinicians and payers because they influence decision-making about when to perform inpatient procedures versus outpatient treatment, affect perioperative morbidity, and alter cost and case mix for DRG 822 admissions.
Post-discharge outcomes and care-transition research focusing on readmission prevention, rehabilitation needs, and outpatient care coordination for patients discharged after major O.R. procedures for lymphoma or leukemia; cohorts include recently discharged inpatients with complex needs (e.g., cytopenias, central lines, or infection risk), and studies test interventions such as structured discharge planning, home nursing support, or early outpatient monitoring to reduce 30-day readmissions and emergency visits. These studies are important to providers and payers because they target downstream utilization and penalties tied to readmissions, impacting overall cost-effectiveness and quality metrics associated with this DRG.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$13K	$69K	$9.7K	680

Perioperative and intraoperative management trials investigating optimized surgical approaches and supportive care for patients with lymphoma or leukemia undergoing major operating room procedures; these studies enroll inpatient adults or children with active hematologic malignancies who require major resections, biopsies, or device implantations and test protocols for transfusion thresholds, perioperative antimicrobial prophylaxis, and strategies to minimize bleeding and infection risk. Research in this area addresses immediate procedural complications and resource utilization, directly informing hospital protocols, length-of-stay, and reimbursement drivers for this DRG.
Comparative effectiveness studies evaluating different systemic therapy sequencing or timing in relation to major O.R. procedures, such as trials comparing neoadjuvant versus adjuvant systemic regimens or timing of chemotherapy relative to surgery; these typically include patients with lymphoma or leukemia where surgical intervention is part of diagnostic management or symptom control, and measure outcomes like complication rates, readmissions, and short-term disease control. Findings are relevant to clinicians and payers because they influence decision-making about when to perform inpatient procedures versus outpatient treatment, affect perioperative morbidity, and alter cost and case mix for DRG 822 admissions.
Post-discharge outcomes and care-transition research focusing on readmission prevention, rehabilitation needs, and outpatient care coordination for patients discharged after major O.R. procedures for lymphoma or leukemia; cohorts include recently discharged inpatients with complex needs (e.g., cytopenias, central lines, or infection risk), and studies test interventions such as structured discharge planning, home nursing support, or early outpatient monitoring to reduce 30-day readmissions and emergency visits. These studies are important to providers and payers because they target downstream utilization and penalties tied to readmissions, impacting overall cost-effectiveness and quality metrics associated with this DRG.

OpenPayer

Summary & Overview

Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

DRG 822 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes